Solara Active Pharma Sciences Past Earnings Performance
Past criteria checks 0/6
Solara Active Pharma Sciences's earnings have been declining at an average annual rate of -72.5%, while the Pharmaceuticals industry saw earnings growing at 13.4% annually. Revenues have been declining at an average rate of 1.7% per year.
Key information
-72.5%
Earnings growth rate
-71.9%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | -1.7% |
| Return on equity | -49.3% |
| Net Margin | -43.9% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
The Market Lifts Solara Active Pharma Sciences Limited (NSE:SOLARA) Shares 26% But It Can Do More
Sep 13
Further Upside For Solara Active Pharma Sciences Limited (NSE:SOLARA) Shares Could Introduce Price Risks After 30% Bounce
Jul 20Slammed 32% Solara Active Pharma Sciences Limited (NSE:SOLARA) Screens Well Here But There Might Be A Catch
Jun 05A Look At The Fair Value Of Solara Active Pharma Sciences Limited (NSE:SOLARA)
May 11Investors Still Aren't Entirely Convinced By Solara Active Pharma Sciences Limited's (NSE:SOLARA) Revenues Despite 28% Price Jump
Apr 19Is Solara Active Pharma Sciences (NSE:SOLARA) A Risky Investment?
Mar 13Even With A 26% Surge, Cautious Investors Are Not Rewarding Solara Active Pharma Sciences Limited's (NSE:SOLARA) Performance Completely
Feb 23Further Upside For Solara Active Pharma Sciences Limited (NSE:SOLARA) Shares Could Introduce Price Risks After 25% Bounce
Jan 04Solara Active Pharma Sciences Limited's (NSE:SOLARA) Intrinsic Value Is Potentially 81% Above Its Share Price
May 12Estimating The Intrinsic Value Of Solara Active Pharma Sciences Limited (NSE:SOLARA)
Nov 08Is Solara Active Pharma Sciences (NSE:SOLARA) A Risky Investment?
Sep 30Are Investors Undervaluing Solara Active Pharma Sciences Limited (NSE:SOLARA) By 22%?
Aug 03Solara Active Pharma Sciences (NSE:SOLARA) Is Making Moderate Use Of Debt
Jun 19Newsflash: Solara Active Pharma Sciences Limited (NSE:SOLARA) Analysts Have Been Trimming Their Revenue Forecasts
Feb 17A Look At The Fair Value Of Solara Active Pharma Sciences Limited (NSE:SOLARA)
Dec 21Revenue & Expenses Breakdown
How Solara Active Pharma Sciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 12,218 | -5,361 | 2,324 | 0 |
| 30 Jun 24 | 13,001 | -5,613 | 2,378 | 0 |
| 31 Mar 24 | 12,889 | -5,674 | 2,500 | 0 |
| 31 Dec 23 | 14,069 | -3,077 | 2,503 | 0 |
| 30 Sep 23 | 15,529 | -325 | 2,461 | 0 |
| 30 Jun 23 | 14,661 | -253 | 2,359 | 0 |
| 31 Mar 23 | 14,438 | -222 | 2,308 | 0 |
| 31 Dec 22 | 14,240 | -241 | 2,150 | 0 |
| 30 Sep 22 | 11,296 | -1,644 | 2,221 | 0 |
| 30 Jun 22 | 11,928 | -1,247 | 2,319 | 0 |
| 31 Mar 22 | 12,683 | -581 | 2,392 | 0 |
| 31 Dec 21 | 13,517 | -34 | 2,529 | 0 |
| 30 Sep 21 | 16,781 | 2,023 | 2,472 | 0 |
| 30 Jun 21 | 16,740 | 2,293 | 2,393 | 0 |
| 31 Mar 21 | 16,169 | 2,214 | 2,327 | 0 |
| 31 Dec 20 | 14,694 | 1,826 | 2,297 | 0 |
| 30 Sep 20 | 13,864 | 1,581 | 2,212 | 0 |
| 30 Jun 20 | 13,400 | 1,304 | 2,139 | 0 |
| 31 Mar 20 | 13,218 | 1,146 | 2,080 | 0 |
| 31 Dec 19 | 14,103 | 1,231 | 2,059 | 0 |
| 30 Sep 19 | 14,228 | 1,039 | 2,032 | 0 |
| 30 Jun 19 | 14,140 | 845 | 1,986 | 0 |
| 31 Mar 19 | 13,867 | 614 | 1,927 | 0 |
| 31 Mar 18 | 5,210 | 60 | 710 | 0 |
Quality Earnings: SOLARA is currently unprofitable.
Growing Profit Margin: SOLARA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SOLARA is unprofitable, and losses have increased over the past 5 years at a rate of 72.5% per year.
Accelerating Growth: Unable to compare SOLARA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SOLARA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (20%).
Return on Equity
High ROE: SOLARA has a negative Return on Equity (-49.26%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 02:09 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Solara Active Pharma Sciences Limited is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Antique Stockbroking Ltd. |
| Kameswari V. S. Chavali | FirstCall Research |
| Rishabh Kale | Indsec Securities & Finance Ltd. |